Skip to main content
. 2017 Jul 13;14(4):842–858. doi: 10.1007/s13311-017-0553-8

Table 5.

Existing anti-CD25 monoclonal antibodies (mAbs)

Generic name Trade name Source Indications
Daclizumab IV ZenapaxTM Humanized mAb No longer manufactured
Basiliximab IV SimulectTM Chimeric mAb Not formally tested in MS
Daclizumab-β SQ ZinbrytaTM Humanized mAb Approved for RRMS

IV = intravenous; SQ = subcutaneous; MS = multiple sclerosis; RRMS = relapsing-remitting MS